98%
921
2 minutes
20
A rapid increase in the number of patients with dementia, particularly memory decline or impairment, has led to the loss of self-care ability in more individuals and increases in medical and social costs. Numerous studies, and clinical service experience, have revealed that the intervention of nonpharmacological management for people with dementia is effective in delaying the degeneration caused by dementia. Due to recent rapid developments in information and communications technology, many innovative research and development and cross-domain applications have been effectively used in the dementia care environment. This study proposed a new short-term memory support and cognitive training application technology, a "positioning and shadowing system," to delay short-term memory degeneration in dementia. Training courses that integrate physical and digital technologies for the indoor location of patients with dementia were constructed using technologies such as Bluetooth Low Energy, fingerprint location algorithm, and short-range wireless communication. The Internet of Things was effectively applied to a clinical training environment for short-term memory. A pilot test verified that the results demonstrated learning effects in cognitive training and that the system can assist medical personnel in training and nursing work. Participants responded with favorable feedback regarding course satisfaction and system usability. This study can be used as a reference for future digital smart cognitive training that allows observation of the performance of patients with dementia in activities of daily living.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915513 | PMC |
http://dx.doi.org/10.3390/ijerph18041610 | DOI Listing |
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFMol Biol Rep
September 2025
Department of Pharmacology, Govt. College of Pharmacy, Rohru, Shimla, Himachal Pradesh, 171207, India.
Alzheimer's disease (AD) is the most common, complex, and untreatable form of dementia which is characterized by severe cognitive, motor, neuropsychiatric, and behavioural impairments. These symptoms severely reduce the quality of life for patients and impose a significant burden on caregivers. The existing therapies offer only symptomatic relief without addressing the underlying silent pathological progression.
View Article and Find Full Text PDFJ Korean Med Sci
September 2025
Department of Neurology, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Background: Readily available treatments for Alzheimer's disease and related dementia (ADRD) include acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists. Non-adherence and early discontinuation of anti-dementia medications are prevalent issues. We aimed to investigate factors associated with suboptimal usage of anti-dementia medications in ADRD.
View Article and Find Full Text PDFAm J Med Genet A
September 2025
Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.
To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome. To evaluate the functionality of the NTG-EDSD for Dementia as part of a dementia screening protocol for adults with Down syndrome, we conducted a cohort analysis of patients aged 40 and older followed at the Massachusetts General Hospital Down Syndrome Program, noting any clinical interpretation of dementia or mild cognitive impairment (MCI). From September 2023 to September 2024, 54 NTG-EDSD responses were collected.
View Article and Find Full Text PDFSleep Adv
August 2025
Division of Public Health, Department of Family and Preventive Medicine, University of Utah, 303 Chipeta Way, Salt Lake City, UT 84013, United States of America.
Individuals with mild cognitive impairment (MCI) demonstrate cognitive decline without major functional impairment and are at increased risk for developing Alzheimer's disease and related dementias (ADRD). Sleep and biobehavioral rhythm disturbances (disruptions in 24-h oscillations in physiology and behavior, including rest-activity patterns and mealtimes) are more than twice as common among patients with MCI than cognitively intact older adults. Importantly, the consequences of sleep and biobehavioral rhythm disruption in MCI extend beyond the patient, also profoundly affecting the spouse/partner.
View Article and Find Full Text PDF